| Literature DB >> 36002897 |
Torbjörn Ivert1,2, Magnus Dalén3,4.
Abstract
BACKGROUND: The aim was to analyze routine preoperative testing for coronavirus disease 2019 (COVID-19) performed to avoid infected cardiac surgical patients transmitting virus during the pandemic.Entities:
Keywords: COVID-19; Cardiac surgery; Preoperative PCR testing
Mesh:
Year: 2022 PMID: 36002897 PMCID: PMC9399586 DOI: 10.1186/s13019-022-01960-1
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.522
Fig. 1Flowchart showing number cases with a SARS-CoV-2 PCR positive test and severity of COVID-19 before, at screening and after open heart surgery in 1870 patients operated on during 2020 and 2021.
Fig. 2Distribution over time of COVID-19 diagnosis in 69 patients with a SARS-CoV-2 PCR positive test among 1870 patients undergoing open heart surgery during 2020 and 2021.Black bars indicated cases with positive test after the operation.
Preoperative characteristic in patients with and without COVID-19 who underwent open cardiac surgery from March 2020 through December 2021.
| COVID-19 | Non COVID-19 | ||
|---|---|---|---|
| Age (years) | 62 (10) | 62 (13) | 0.90 |
| Female gender | 27 (39.1) | 446 (24.8) | 0.01 |
| BMI (kg/m2) | 28.4 (5) | 27.0 (6) | 0.04 |
| Creatinine (µmol/L) | 79.4 (25.0) | 86 (39.1) | 0.15 |
| EuroSCORE II | 4.0 (6.5) | 4.6 (6.9) | 0.40 |
| Previous smoking | 36 (52.1) | 717 (39.8) | 0.23 |
| Hypertension | 47 (68.1) | 1044 (58.0) | 0.12 |
| Hyperlipidaemia | 39 (56.5) | 901 (50.0) | 0.35 |
| Diabetes mellitus | 20 (29.0) | 341 (18.9) | 0.05 |
| COPD | 12 (17.4) | 159 (8.8) | 0.01 |
| LVEF ≤ 50% | 45 (65.2) | 524 (29.0) | < 0.001 |
BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation Score II [6]; LVEF, left ventricular ejection fraction.
a38 (55%) previous COVID-19, 15 (22%) positive on admission, 16 (23%) postoperative COVID-19. Data presented as numbers with percent or mean with one standard deviation
Operative data and early postoperative outcome in patients with and without COVID-19 who had cardiac surgery from March 2020 through December 2021.
| COVID-19 | Non COVID-19 | ||
|---|---|---|---|
| Urgent operation | 28(40.6) | 608(33.8) | |
| Emergent operation | 3(4.3) | 106(5.9) | |
| Valve surgery | 33(47.8) | 756(42.0) | 0.19 |
| Isolate CABG | 27(39.1) | 591(32.8) | 0.34 |
| Valve and CABG | 1(1.4) | 75(4.2) | 0.44 |
| Aortic surgery | 5(7.2) | 286(15.9) | 0.76 |
| Other procedures | 3(4.3) | 93(5.2) | 0.98 |
| Mortality ≤ 30 days | 1 (0.9) | 20 (1.1) | 0.77 |
| Re-entry for bleeding | 2 (2.9) | 84 (4.7) | 0.74 |
| Stroke | 0 | 40 (2.2) | 0.42 |
| Respirator ≥ 2 days | 2 (2.9) | 34 (1.9) | 0.84 |
| Atrial fibrillation | 11 (15.9) | 374 (20.8) | 0.50 |
| Pleuracentesis | 5 (7.2) | 70 (3.9) | 0.24 |
| Pericardiocentesis | 3 (4.3) | 31 (1.7) | 0.23 |
Data presented as numbers with percent
CABG, coronary artery bypass grafting
Fig. 3Distribution over time of 326,995 subjects with a SARS-CoV-2 PCR positive test among the population of 975,500 inhabitants (34%) in Stockholm during 2020 and 2021 Official statistics from The Public Health Agency of Sweden (https://www.folkhalsomyndigheten.se).